Wang Qu

机构：Guangdong Medical College

发表论文 41 篇 · 总被引 104 次 · h-index 5

代表论文

• Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial (2023 · BMC Medicine · 被引 45)
• First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 10)
• Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China (2024 · BMC Cancer · 被引 10)
• MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer. (2022 · Journal of Clinical Oncology · 被引 7)
• A culture-free method for rapidly and accurately quantifying active SARS-CoV-2 (2023 · Analytical and Bioanalytical Chemistry · 被引 3)
• 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study (2022 · Annals of Oncology · 被引 2)